Locate your nearest distributor

Location:
Type:
Text search:
Username:
Password:
Forgot password?

News Archive

Biohit Group Financial Statement Release 2017

28.02.2018 09:30

Biohit Oyj Financial Statement Release, 28 February 2018 at 9:30 am local time (EET)
 
 
SUMMARY
 
January-December 2017
 
Net sales grew by 9.6 % compared to 2016
Net sales EUR 9.0 million (EUR 8.2 million)
EBITDA EUR 7.9. million (EUR -3.0 million)
Operative EBITDA EUR -0.4 million (EUR -1.9 million)
Operating profit EUR 6.4 million (EUR -3.4 million)
The profit for the reporting period was EUR 6.1 million (EUR -3.3 million)
Net sales from international operations 95.7 % (92.2 %) of total net sales
Equity ratio 91.3 % (83.0 %)
July-December 2017
 
Net sales grew by 12.0 % compared to H2/2016
Net sales EUR 4.9 million (EUR 4.4 million)
EBITDA EUR 0.3 million (EUR -1.1 million)
Operative EBITDA EUR 0.3 million (EUR -0.7 million)
Operating profit EUR -1.0 million (EUR -1.3 million)
The loss for the reporting period was EUR -1.1 million (EUR -1.2 million)
Net sales from international operations 96.2 % (93.7 %) of total net sales
Equity ratio 91.3 % (83.0 %)
Biohit Group presents certain alternative performance measures (APM) to reflect the underlying business performance and to enhance comparability between financial periods. Alternative performance measures should not be considered in isolation as a substitute for measures of performance in accordance with IFRS. Definitions and reconciliation of key figures are presented in the financial section of the release.
 
 
PRESIDENT & CEO SEMI KORPELA:
 
In 2017, we further improved our sales and financial result. We developed our products and made progress in our research projects. Our EBITDA adjusted for items affecting comparability was EUR -0.4 million (EUR -1.9 million), which represents an improvement of EUR 1.6 million on the comparison period. Our free cash flow in the 2017 financial period amounted to EUR 0.6 million (EUR -2.5 million). Our financing position was strengthened by the cash sum from the divestment of our joint venture, which amounted EUR 1.5 million after tax and change in foreign exchange rates. Our Chinese business developed favourably in 2017, and we expect the outlook to remain good. Biohit is well positioned to continue growing in 2018.
 
read more